Apalunix

Apalutamide is an orally administered, selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide prevents AR nuclear translocation, inhibits DNA binding, impedes AR-mediated transcription, and lacks androgen receptor agonist activity. Apalutamide treatment decreases tumor cell proliferation and increases apoptosis leading to potent antitumor activity.

Apaluda is an androgen receptor inhibitor indicated for the treatment of patients with- metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.

Features